'Outstanding' 5 Year PFS With Lorlatinib in ALK+ NSCLC

Five-year follow-up data from the landmark CROWN trial shows significant progression-free survival in ALK+ NCSLC, but some experts question the use of crizotinib as the comparator drug.
Medscape Medical News

source https://www.medscape.com/viewarticle/outstanding-5-year-progression-free-survival-lorlatinib-alk-2024a1000aas?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?